Biotech Vertex Pharmaceuticals stock tumbled on news of disappointing drug data. CEO Reshma Kewalramani paid nearly $4 ...

The heritage British brand has been revived by a chairman whose impressive career before watchmaking includes a three-year ...

Vertex Pharmaceuticals' unchanged guidance and disappointing trial outcomes for its investigative pain relief treatment led ...

Vertex Pharmaceuticals' Seaport headquarters buildings have been refinanced for $1 billion, putting a ten-figure value on an ...

And one of the best ways to cash in on that is to invest in stocks that can exceed the market's performance. Two that look ...

It's the second time this year the stock has slumped significantly in one day, and it might represent another attractive ...

Vertex Pharmaceuticals Incorporated's stock drop is overblown. With strong CF revenue, pipeline potential, & insider ...

A federal judge ruled Hampton’s Zoning Board had ample evidence to reject the tower, but left one legal claim standing.

Vertex Resource Group Ltd. ("Vertex" or the "Company") reports its financial and operational results for the second quarter ...

Vertex Pharmaceuticals’ second quarter 2025 results exceeded Wall Street’s expectations, but the market responded sharply ...

The RMR Group secured a $1 billion refinancing for Vertex Pharmaceuticals' Boston Seaport headquarters, a five-year, interest ...

Vertex Corp. (5290.TO) Japan 1st Quarter Ended June 30 GROUP 2025 2024 Revenue Y8.70 bln Y8.24 bln Operating Profit Y1.08 bln Y781.00 mln Pretax Profit Y1.15 bln Y830.00 mln Net Profit Y658.00 mln ...